Barclays’s Cytokinetics CYTK Stock Holding History

Barclays’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-104,700	Closed	-$6.9M	–	5408
2026 Q1	$6.9M	Sell	104,700 -27,500	-21%	-$1.75M	﹤0.01%	1637
2025 Q4	$8.4M	Sell	132,200 -400	-0.3%	-$24.9K	﹤0.01%	1818
2025 Q3	$7.29M	Buy	132,600 +132,400	+66,200%	+$5.45M	﹤0.01%	1920
2025 Q2	$6.61K	Buy	+200	New	+$6.96K	﹤0.01%	4950
2025 Q1	–	Sell	-10,000	Closed	-$470K	–	5313
2024 Q4	$470K	Hold	10,000	–	–	﹤0.01%	3861
2024 Q3	$528K	Sell	10,000 -70,000	-88%	-$3.9M	﹤0.01%	3743
2024 Q2	$4.33M	Buy	80,000 +52,000	+186%	+$3.14M	﹤0.01%	1630
2024 Q1	$1.96M	Sell	28,000 -677,800	-96%	-$52.4M	﹤0.01%	2586
2023 Q4	$58.9M	Buy	705,800 +688,000	+3,865%	+$24.9M	0.02%	593
2023 Q3	$524K	Buy	+17,800	New	+$593K	﹤0.01%	2784
2020 Q4	–	Sell	-5,500	Closed	-$119K	–	4928
2020 Q3	$119K	Buy	+5,500	New	+$129K	﹤0.01%	4153
2017 Q4	–	Sell	-50,500	Closed	-$732K	–	6945
2017 Q3	$732K	Buy	+50,500	New	+$690K	﹤0.01%	3274
2014 Q2	–	Sell	-200	Closed	-$2K	–	7626
2014 Q1	$2K	Buy	+200	New	+$1.81K	﹤0.01%	7395

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's CYTK Position: Q2 2026 in Review

Barclays reduced its Cytokinetics (CYTK) stake by 11% in Q2 2026, selling an estimated $612K and leaving 70,642 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Barclays first reported a position in CYTK in Q3 2013 and has held it in 52 quarters since. The position peaked at $53.4M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Barclays held 70,642 shares of Cytokinetics worth $6.02M as of Q2 2026.
Barclays sold 8,517 Cytokinetics shares in Q2 2026, an estimated $612K.
Cytokinetics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1743 holding.
Barclays first reported a position in Cytokinetics in Q3 2013 and has held it in 52 quarters since.
Barclays's Cytokinetics position peaked at $53.4M in Q1 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.